Inventor · disambiguated record
Dajun Yang
Also filed as: YANG DAJUN
31 granted patents·35 pending applications·158 citations·filing 1997–2025
95Inventor score
Files withASCENTAGE PHARMA SUZHOU CO LTD41UNIV MICHIGAN8UNIV GEORGETOWN4ASCENTA THERAPEUTICS INC3JIANGSU ASCENTAGE BIOMED DEV INC3
Top patents by PatentIndex Score
66 records- 0194US11850239B2MDM2 inhibitor and a platinum compound for cancer treatmentASCENTAGE PHARMA SUZHOU CO LTD·Filed 2020·Granted Dec 26, 2023·3 cites·20 claims
- 0294US6703382B2Small molecule inhibitors targeted at Bcl-2UNIV GEORGETOWN MED CENTER·Filed 2001·Granted Mar 9, 2004·81 cites·8 claims
- 0390US11452716B2Pharmaceutical composition and use thereofASCENTAGE PHARMA SUZHOU CO LTD·Filed 2020·Granted Sep 27, 2022·3 cites·20 claims
- 0487US8557812B2Small molecule inhibitors of anti-apoptotic BCL-2 family members and the uses thereofWANG SHAOMENG·Filed 2005·Granted Oct 15, 2013·9 cites·7 claims
- 0587US7354928B2Small molecule inhibitors targeted at Bcl-2UNIV MICHIGAN·Filed 2002·Granted Apr 8, 2008·22 cites·20 claims
- 0684US7432304B2Small molecule antagonists of Bcl-2 family proteinsUNIV MICHIGAN·Filed 2003·Granted Oct 7, 2008·16 cites·37 claims
- 0783US11478469B2Combination product of BCL-2 inhibitor and MDM2 inhibitor and use thereof in the prevention and/or treatment of diseasesASCENTAGE PHARMA SUZHOU CO LTD·Filed 2019·Granted Oct 25, 2022·2 cites·10 claims
- 0880US7910621B2Small molecule antagonists of XIAP family proteinsUNIV MICHIGAN·Filed 2005·Granted Mar 22, 2011·5 cites·22 claims
- 0978US12268665B2Combination of immunotherapies with MDM2 inhibitorsASCENTAGE PHARMA SUZHOU CO LTD·Filed 2019·Granted Apr 8, 2025·1 cites·13 claims
- 1078US11395815B2Compound for treating osteoarthritisASCENTAGE PHARMA SUZHOU CO LTD·Filed 2020·Granted Jul 26, 2022·1 cites·14 claims
- 1178US8163805B2Small molecule antagonists of Bcl-2 family proteinsWANG SHAOMENG·Filed 2008·Granted Apr 24, 2012·2 cites·20 claims
- 1276US7259142B2Redox-stable, non-phosphorylated cyclic peptide inhibitors of SH2 domain binding to target protein, conjugates thereof, compositions and methods of synthesis and useUS HEALTH·Filed 2005·Granted Aug 21, 2007·1 cites·7 claims
- 1373US11298339B2Bisdiazabicyclo compound for treatment and/or prevention of hepatitis virus-related diseases or disordersJIANGSU ASCENTAGE BIOMED DEV INC·Filed 2018·Granted Apr 12, 2022·1 cites·5 claims
- 1473US7226991B1Phenylalanine derivativesUNIV GEORGETOWN·Filed 2000·Granted Jun 5, 2007·3 cites·49 claims
- 1572US2024390401A1Combination of bcl-2/bcl-xl inhibitors and chemotherapeutic agent and use thereofASCENTAGE PHARMA SUZHOU CO LTD·Filed 2024·Application pending·0 cites
- 1668US9783539B2Indoloquinolone compounds as anaplastic lymphoma kinase (ALK) inhibitorsJIANGSU ASCENTAGE BIOMED DEV INC·Filed 2014·Granted Oct 10, 2017·2 cites·20 claims
- 1767US12083136B2Combination of BCL-2/BCL-XL inhibitors and chemotherapeutic agent and use thereofASCENTAGE PHARMA SUZHOU CO LTD·Filed 2019·Granted Sep 10, 2024·0 cites·4 claims
- 1865US2010069344A1Small molecule antagonists of bcl2 family proteinsUNIV MICHIGAN·Filed 2009·Application pending·0 cites
- 1965US2008058322A1Small molecule inhibitors targeted at Bcl-2UNIV MICHIGAN·Filed 2007·Application pending·0 cites
- 2064US2025281511A1N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitorsASCENTAGE PHARMA SUZHOU CO LTD·Filed 2025·Application pending·0 cites
- 2163US12370197B2Combination product of a Bcl-2/Bcl-xL inhibitor and a chemotherapeutic agent and use thereof in the prevention and/or treatment of diseasesASCENTAGE PHARMA SUZHOU CO LTD·Filed 2020·Granted Jul 29, 2025·0 cites·8 claims
- 2263US12233047B2Pharmaceutical combination and use thereofASCENTAGE PHARMA SUZHOU CO LTD·Filed 2020·Granted Feb 25, 2025·0 cites·20 claims
- 2363US2025152580A1Methods for treating immune diseasesASCENTAGE PHARMA SUZHOU CO LTD·Filed 2023·Application pending·0 cites
- 2463US2022193071A1Methods for cancer therapyASCENTAGE PHARMA SUZHOU CO LTD·Filed 2019·Application pending·0 cites
- 2562US12343352B2N-(phenylsulfonyl)benzamides and related compounds as Bcl-2 inhibitorsASCENTAGE PHARMA SUZHOU CO LTD·Filed 2020·Granted Jul 1, 2025·0 cites·12 claims
- 2662US11491167B2Combination product of Bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseasesASCENTAGE PHARMA SUZHOU CO LTD·Filed 2019·Granted Nov 8, 2022·0 cites·11 claims
- 2762US2022296571A1Bisdiazabicyclo compound for treating and/or preventing hepatitis virus-related diseases or disordersJIANGSU ASCENTAGE BIOMED DEV INC·Filed 2022·Application pending·0 cites
- 2862US2009118377A1Apogossypolone and the uses thereofUNIV MICHIGAN·Filed 2009·Application pending·0 cites
- 2960US2023404998A1Combination Therapies for Treating CancerASCENTAGE PHARMA SUZHOU CO LTD·Filed 2023·Application pending·0 cites
- 3060US2025114329A1Methods for treating aml-mrc and mdsASCENTAGE PHARMA SUZHOU CO LTD·Filed 2023·Application pending·0 cites
- 3159US11554127B2Synergistic antitumor effect of Bcl-2 inhibitor combined with rituximab and/or bendamustine or Bcl-2 inhibitor combined with CHOPASCENTAGE PHARMA SUZHOU CO LTD·Filed 2019·Granted Jan 17, 2023·0 cites·12 claims
- 3259US2025099440A1A pharmaceutical combination and use thereofASCENTAGE PHARMA SUZHOU CO LTD·Filed 2022·Application pending·0 cites
- 3357US2025235426A1Pharmaceutical Combination and Use ThereofASCENTAGE PHARMA SUZHOU CO LTD·Filed 2025·Application pending·0 cites
- 3457US2024316051A1A pharmaceutical combination and use thereofASCENTAGE PHARMA SUZHOU CO LTD·Filed 2022·Application pending·0 cites
- 3557US2024366611A1Methods of treating a disease or disorderASCENTAGE PHARMA SUZHOU CO LTD·Filed 2022·Application pending·0 cites
- 3656US2024316069A1Methods of treating multiple sclerosisASCENTAGE PHARMA SUZHOU CO LTD·Filed 2021·Application pending·0 cites
- 3756US2023381176A1A pharmaceutical composition and use thereof for treatment of cancerASCENTAGE PHARMA SUZHOU CO LTD·Filed 2021·Application pending·0 cites
- 3856US2023398110A1Compositions and methods for treating non-alcoholic steatohepatitisASCENTAGE PHARMA SUZHOU CO LTD·Filed 2021·Application pending·0 cites
- 3955US2023149356A1Novel medical use of mdm2 inhibitorsASCENTAGE PHARMA SUZHOU CO LTD·Filed 2021·Application pending·0 cites
- 4054US12287338B2Method and compositions for predicting anti-cancer efficacy of compounds targeting apoptosis pathwayASCENTAGE PHARMA SUZHOU CO LTD·Filed 2020·Granted Apr 29, 2025·0 cites·12 claims
- 4154US2023301989A1Compositions and methods for treating systemic lupus erythematosusASCENTAGE PHARMA SUZHOU CO LTD·Filed 2021·Application pending·0 cites
- 4254US2023078120A1Methods for Treating Coronavirus InfectionsASCENTAGE PHARMA SUZHOU CO LTD·Filed 2021·Application pending·0 cites
- 4354US2022296557A1Combinations of bcl-2/bcl-xl inhibitors and related usesASCENTAGE PHARMA SUZHOU CO LTD·Filed 2021·Application pending·0 cites
- 4454US2006178435A1Apogossypolone and the uses thereofUNIV MICHIGAN·Filed 2005·Application pending·0 cites
- 4553US7427689B2ErbB-2 selective small molecule kinase inhibitorsUNIV GEORGETOWN·Filed 2001·Granted Sep 23, 2008·0 cites·3 claims
- 4653US2021275522A1Pharmaceutical compositions and use thereofASCENTAGE PHARMA SUZHOU CO LTD·Filed 2019·Application pending·0 cites
- 4752US12194024B2Pharmaceutical composition of MDM2 inhibitor and use thereof for preventing and/or treating diseaseASCENTAGE PHARMA SUZHOU CO LTD·Filed 2020·Granted Jan 14, 2025·0 cites·5 claims
- 4852US12186304B2Method for treating cancer by combination of IAP inhibitor and modulator of immune checkpoint moleculeASCENTAGE PHARMA SUZHOU CO LTD·Filed 2019·Granted Jan 7, 2025·0 cites·22 claims
- 4952US11491168B2Combination of Bcl-2/Bcl-xL inhibitors and chemotherapeutic agent and use thereofASCENTAGE PHARMA SUZHOU CO LTD·Filed 2020·Granted Nov 8, 2022·0 cites·11 claims
- 5052US11478477B2Method for treating cancer by combination of FAK/ALK/ROS1 inhibitor and EGFR inhibitorASCENTAGE PHARMA SUZHOU CO LTD·Filed 2019·Granted Oct 25, 2022·0 cites·18 claims
Showing the top 50 of 66 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Dajun Yang files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →